Company profile
Lattice Biologics Ltd.
OTC: LBLTF · Healthcare · Medical - Devices
#778 of 1,422 Healthcare companies by revenue59th-percentile growth
EA Score
——FH —DQ —GM —SS 41
v0.1 · 5/100 weight · pillars only
↑ listing tenure, operating margin · ↓ growth stability, market scale
Methodology →Revenue TTM
$1.6M
Rev growth YoY (TTM)
-28.9%
Net income (FY)
-$1.5M
Employees
—
as of 2026-08-29
Market cap
$16.5k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.5M$2.5M2020
Net income-$1.5M-$1.5M2020
Operating income-$336.0k-$336.0k2020
Total assets$3.0M$3.0M2020
Liabilities$9.4M$9.4M2020
Equity-$6.4M-$6.4M2020
Revenue trend
FY2013 – FY2020 · USD
FY13
FY14
FY15
FY16
FY17
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lattice Biologics Ltd.’s revenue?
Lattice Biologics Ltd. booked $2.5M in FY2020 revenue, growing 13% year over year — about the middle of the pack among Healthcare companies we track, at a -60.2% net margin.
Peers · Healthcare
Fiore Cannabis Ltd.——GeoVax Labs, Inc.38DWayland Group Corp.——Quantum-Si incorporated40DDNAPrint Genomics, Inc.——Panacea Life Sciences Holdings, Inc.——Neighbors
Gallatin →Key facts
CEODonna Medina
SectorHealthcare
IndustryMedical - Devices
HeadquartersBelgrade, MT
ExchangeOTC: LBLTF
Employees—
IPO date2010-12-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.